OBJECTIVES: To summarize cost-effectiveness of bortezomib (BTZ) for multiple myeloma (MM) and identify bias in the published cost-effectiveness analysis (CEA). METHODS: Electronic bibliographic databases were searched from 2003 to 2014 for eligible CEA. The full publications of included CEAs were reviewed for data extraction. The  reported base case incremental cost-effectiveness ratio per gained quality adjusted life year (QALY) or life year (LY) were converted to the ratio to 2013 country-specific gross domestic product per capita (GDPPC) to interpret cost-effectiveness according to World Health Organization (WHO) recommendation on cost-effectiveness threshold (3 GDPPC). The study designs and methods of the included CEAs were assessed regarding their impact on cost-effectiveness.  RESULTS: CONCLUSIONS: BTZ was cost-effective for MM prior to SCT, MM ineligible for SCT, and relapse/refractory MM when compared to conventional treatments. However, caution is needed when interpreting the cost-effectiveness of BTZ relative to MPT and MPR-R for MM ineligible for SCT or LEN/DEX for relapse/refractory MM due to the potential bias associated with indirect comparisons.